Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(29%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
5
71%
Ph phase_2
1
14%
Ph early_phase_1
1
14%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)

Detailed Status

Withdrawn2
Completed2
Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 15 (71.4%)
Phase 21 (14.3%)

Trials by Status

active_not_recruiting114%
withdrawn229%
completed229%
recruiting114%
terminated114%

Recent Activity

2 active trials
Showing 5 of 7
active_not_recruitingphase_1

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031
recruitingphase_1

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

NCT05440708
withdrawnphase_1

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT05668949
withdrawnearly_phase_1

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

NCT05845307
completedphase_2

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

NCT05671835
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06141031Phase 1

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Active Not Recruiting
NCT05440708Phase 1

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
NCT05668949Phase 1

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Withdrawn
NCT05845307Early Phase 1

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Withdrawn
NCT05671835Phase 2

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Completed
NCT03195699Phase 1

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Completed
NCT05384119Phase 1

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7